BioNTech

BioNTech is a biotechnology company headquartered in Mainz, Germany, whose American depositary shares trade on the Nasdaq (NASDAQ: BNTX). It is best known for Comirnaty, the messenger RNA (mRNA) COVID-19 vaccine it co-developed with Pfizer, and its pipeline has since shifted toward cancer. It appears here not as an AI vendor but as a large AI adopter that went one step further and bought an AI company outright. BioNTech itself sells no AI product; its subsidiary InstaDeep still does AI work for clients outside medicine.

Its defining pattern is acquirer-integrator. The two companies began working together in 2019, formed a joint AI Innovation Lab in November 2020, and in January 2022 announced an Early Warning System for spotting high-risk coronavirus variants. In January 2023 BioNTech agreed to buy the rest of InstaDeep for about 362 million pounds upfront in cash and shares, plus up to about 200 million pounds in performance-based milestones, and it closed the deal in July 2023, adding about 290 staff. Chief executive Ugur Sahin framed the goal as making BioNTech "a technology company where AI is seamlessly integrated into all aspects of our work." InstaDeep runs as a London-based subsidiary, and in May 2025 the company named its new United Kingdom headquarters as the home of its AI hub.

What the purchase bought is an in-house AI stack. Kyber, InstaDeep's supercomputer, launched in 2024, and at the company's October 2025 AI Day it was described as roughly 500 petaflops of Nvidia H100 chips with more than 80,000 processor cores. On it run models InstaDeep builds and publishes: the Nucleotide Transformer family for reading genomes, Bayesian flow network models that generate protein and antibody sequences, and InstaNovo, a peptide-sequencing model BioNTech says it uses to find new tumor targets. It also buys outside data: Tempus AI reported signing a large data deal with BioNTech in the second quarter of 2026.

The clearest test is its individualized cancer vaccine, autogene cevumeran, developed with Genentech, part of Roche. Each patient's tumor is sequenced, software ranks which mutations the immune system is likely to recognize, and a personal mRNA vaccine is made. The machine learning sits in that ranking step, where BioNTech says it invested early in trained prediction algorithms; the vaccine itself is ordinary mRNA. By October 2025 more than 450 patients had been treated. In August 2026 BioNTech ended the colorectal cancer trial of the vaccine given alone, after an independent board saw an imbalance in overall survival; a pancreatic cancer trial pairing it with chemotherapy continues. Leadership is changing too: its co-founders plan to leave for a new mRNA company, and Guido Oelkers was named incoming chief executive in August 2026.

The honest framing: BioNTech's value rests on Comirnaty and a late-stage cancer pipeline, with AI as a lever it owns rather than rents. The supercomputer and published models are measured outputs; better medicines are still the intention, and the first big clinical test of AI-ranked targets has produced one failed trial and one still running. Among catalog peers, Gilead procures specialists, Eli Lilly productized its own models through TuneLab, Moderna built hundreds of models in-house, Merck & Co. runs one enterprise platform with Google Cloud, and Novo Nordisk spreads work across OpenAI, Amazon Web Services and Anthropic. AstraZeneca also bought an AI company, the pathology specialist Modella AI, but BioNTech bought a whole AI firm with its own supercomputer and outside clients.